Rearrangements of the Mixed Lineage Leukemia (MLL/KMT2A) gene are present in approximately 10% of acute leukemias and characteristically define disease with poor outcome. Driven by the unmet need to develop better therapies for KMT2A-rearranged leukemia, we previously discovered that the novel anti-cancer agent, curaxin CBL0137, induces decondensation of chromatin in cancer cells, delays leukemia progression and potentiates standard of care chemotherapies in preclinical KMT2A-rearranged leukemia models. Based on the promising potential of histone deacetylase (HDAC) inhibitors as targeted anti-cancer agents for KMT2A-rearranged leukemia and the fact that HDAC inhibitors also decondense chromatin via an alternate mechanism, we investigated whether CBL0137 could potentiate the efficacy of the HDAC inhibitor panobinostat in KMT2A-rearranged leukemia models. The combination of CBL0137 and panobinostat rapidly killed KMT2A-rearranged leukemia cells by apoptosis and significantly delayed leukemia progression and extended survival in an aggressive model of MLL-AF9 (KMT2A:MLLT3) driven murine acute myeloid leukemia. The drug combination also exerted a strong anti-leukemia response in a rapidly progressing xenograft model derived from an infant with KMT2A-rearranged acute lymphoblastic leukemia, significantly extending survival compared to either monotherapy. The therapeutic enhancement between CBL0137 and panobinostat in KMT2A-r leukemia cells does not appear to be
mediated through cooperative effects of the drugs on KMT2A rearrangement-associated histone modifications. Our data has identified the CBL0137/panobinostat combination as a potential novel targeted therapeutic approach to improve outcome for KMT2A-rearranged leukemia.

Keywords: KMT2A-rearranged leukemia, infant leukemia, curaxin CBL0137, histone deacetylase inhibition, chromatin

INTRODUCTION

Approximately 10% of leukemias harbor a rearrangement of the Mixed Lineage Leukemia (MLL) gene, now renamed KMT2A [reviewed in (1)]. The prevalence of KMT2A gene rearrangements is bimodal with translocations found in up to 80% of infants (diagnosed at less than 1 year of age) with acute lymphoblastic leukemia (ALL) and in young to middle-aged adults with acute myeloid leukemia (AML) (1, 2). The outcome of KMT2A-rearranged (KMT2A-r) leukemia is characteristically poor, especially in infants. The 5-year event-free survival (EFS) for infant KMT2A-r ALL remains below 50% despite the implementation of risk stratification and the use of intensified chemotherapy treatment protocols and stem cell transplantation in high-risk infants (3). Moreover, the established treatment protocols have detrimental long-term health effects. This is particularly relevant in the setting of infant and childhood KMT2A-r leukemia, as these young patients receive high doses of chemotherapeutic agents for extended periods of time, often resulting in developmental delay and decreased quality of life decades later (4). Given that the number of childhood leukemia survivors is on the rise, the detrimental consequences of conventional treatments on long-term health are becoming ever more evident. The search for more potent and safer treatment strategies for KMT2A-r leukemia thus remains an area of pressing unmet clinical need.

We previously found that a novel, non-genotoxic drug, curaxin CBL0137, currently in clinical trials for adult and pediatric malignancies (NCT03727789, NCT01905228, NCT04870944), inhibited leukemia progression and extended survival in KMT2A-r leukemia models, including infant KMT2A-r ALL (5). CBL0137 exerts its anti-cancer effect through intercalating into DNA and inducing genome-wide nucleosome destabilization that activates a cascade of anticancer effects, including trapping the histone chaperone Facilitates Chromatin Transcription (FACT) on chromatin, inhibition of DNA damage repair, p53 activation, NFkB suppression, and induction of TRAIL (Transcription of Repeats Activates Interferon) (5–7).

Effective therapeutic management of high-risk cancers requires innovative combination strategies. While we showed that CBL0137 impressively potentiates standard of care chemotherapies in models of KMT2A-r leukemia (5), the identification of a potent and well-tolerated combination of CBL0137 with a more targeted therapeutic approach is of high clinical relevance. Based on previous studies highlighting the promising preclinical efficacy of histone deacetylase (HDAC) inhibitors against KMT2A-r leukemia (8, 9), we here investigated the preclinical efficacy of a novel combination of targeted drugs, CBL0137 and the HDAC inhibitor panobinostat, in KMT2A-r leukemia models.

MATERIALS AND METHODS

Chemicals and Reagents
CBL0137 was provided by Incuron, Inc. Panobinostat and entinostat (MS-275) were purchased from Sapphire Bioscience Pty Ltd. (Redfern, New South Wales, Australia).

Cell Lines, Cell Culture and Cell-Based Assays
All cell lines used in this study were mycoplasma-free and have been authenticated using STR profiling in the past 3 years. Cell culturing and assays measuring apoptosis and cell cycle were performed as previously described (10, 11). In apoptosis assays, cells were stained with annexin V and 7-Aminoactinomycin D (7-AAD) according to supplier specifications (BD Biosciences, North Ryde, New South Wales, Australia). In synergy viability assays, cells were treated with increasing doses of drugs in a 6x6 combination matrix format. Cell viability was measured by resazurin reduction-based assays after a 5-day treatment. Synergy was scored according to the Bliss Independence model and visualized by Combenefit as previously described (12).

Soft Agar Colony Formation Assays
Six-well plates were coated with a layer of RPMI medium containing 10% FBS and 0.5% agar (agarose, Lonza). Cells were seeded at a density of 800 cells/well in RPMI containing 10% fetal bovine serum, 0.33% agar in the presence of vehicle, CBL0137, panobinostat or the combination. After 14 days, colonies were stained with MTT and counted as previously described (13). In synergy colony assays, cells were treated at incremental doses of CBL0137 or panobinostat as single agent or at a fixed 50:1 ratio for the combination. The occurrence of synergy was assessed based on the Bliss Independence model as previously described (14). Bliss prediction curves indicate the predicted percentage of colonies of treated cells relative to controls when the combination of compounds works additively together. Synergy is visualized as the presence of a lower percentage of colonies upon combination of two compounds compared to the colony percentage predicted based on the presence of an additive effect of the compounds (i.e., the dose-
response curve of the combination runs below the Bliss prediction curve).

**Western Blotting**

Western blotting on lysates from cells and mouse splenocytes was performed as previously described (12). The following antibodies were used: anti-P53 (554293, BD Biosciences), anti-yH2AX (97185, Cell Signaling Technology, New England Biolabs, Notting Hill, Victoria, Australia), anti-IFIT3 (ABF1048, Millipore, Bayswater, Victoria, Australia) anti-H3Ac (06-599, Millipore), anti-H3K27Ac (4353S, Cell Signaling Technology), anti-Histone H3 (total, 9715, Cell Signaling Technology), anti-H3K4Me3 (9751, Cell Signaling Technology), anti-actin (A2066, Sigma, North Ryde, New South Wales, Australia), anti-GAPDH (2118, Cell Signaling Technology).

**IP-10 AlphaLISA**

IP-10 concentrations in mouse serum samples were quantified using the mIP-10/CXCL10 AlphaLISA immunoassay kit (PerkinElmer, Waverley, Victoria, Australia) according to manufacturers’ instructions with minor modifications. Using a 1536-wells Alphaplate (PerkinElmer), 1 µl AlphaLISA buffer was added to each well, followed by 0.25 µl diluted serum, then 0.25 µl of 10x acceptor/biotin mix. After 1 hour, 1 µl of 2.5x donor beads was added, incubated for another hour before reading the plate on the PerkinElmer Envision. All sample and bead additions were done using the Echo acoustic dispenser (Beckman Coulter, Lane Cove, New South Wales, Australia). The mIP-10 standard curve was made up in fetal bovine serum (FBS) and all test samples were diluted 4-fold in FBS due to signal inhibition by undiluted sample matrix. Spike recovery experiments showed good recovery (>80%) after >4-fold sample dilution. The assay lower detection limit was determined to be 100 pg/ml.

**RNA Isolation and qRT-PCR**

RNA isolation and qRT-PCR were performed as described (11, 15).

**Histone Isolation and Dot Blotting**

Histones were purified from splenocytes isolated from treated patient-derived xenograft mice with the EpiQuik Total Histone Extraction Kit (Epigentek, Sapphire Bioscience Pty. Ltd.) according to the manufacturers’ instructions. 0.375 µg histone prep (in 1.5 µl total volume) was spotted onto a nitrocellulose membrane. After drying of the membrane, the staining protocol prep (in 1.5 µl total volume) was spotted onto a nitrocellulose membrane. After drying of the membrane, the staining protocol

**Animal Experiments**

All animal experiments were approved by the University of New South Wales Animal Care and Ethics Committee according to the Animal Research Act 1985, and the Australian Code of Practice for Care and Use of Animals for Scientific Purposes (2013). Efficacy studies with CBL0137 and panobinostat in the MLL-AF9; NRasG12D AML mouse model and the MLL-6 KMT2A-r AML patient-derived xenograft (PDX) model were performed in C57BL/6 and NOD/SCID mice respectively, as previously described (5, 12, 16, 17). Individual mouse event-free survival (EFS) was calculated as the days from treatment initiation until mice reached a total score of 3 in body condition scoring (based on coat condition, activity and body weight) together with bioluminescent evidence of engraftment in the MLL-AF9 (KMT2A:MLLT3);NRasG12D AML model or until the % huCD45+ cells reached 25% in the MLL-6 PDX model. Applied drug doses were determined based on maximally tolerated dose studies and previously performed efficacy studies. In the MLL-AF9;NRasG12D AML mouse model, 60 mg/kg CBL0137 was administered via oral gavage twice a week for two weeks. Panobinostat (7.5 mg/kg) or vehicle (5% dextrose) was administered intraperitoneally five days/week for two weeks. In the KMT2A-r ALL PDX model, CBL0137 (45 mg/kg in 5% dextrose) was administered intravenously twice a week for three weeks. Panobinostat (5 mg/kg) was administered intraperitoneally five days/week for two weeks. For combination studies, panobinostat and CBL0137 were administered according to their individual regimens. To evaluate interactions between drugs in vivo, Therapeutic Enhancement was concluded if the EFS of mice treated with the drug combination was significantly greater (P < 0.01) than the EFS induced by both single agents as determined by Gehan-Wilcoxon (12, 18).

**Statistical Analysis**

GraphPad Prism Version 8 was used for all statistical analyses. EFS curves were compared by Gehan-Wilcoxon analysis. Comparisons of variables between groups were performed as indicated in individual figure legends. P values <0.05 were considered significant.

**RESULTS**

The Combination of CBL0137 and Panobinostat Delays Leukemia Progression in an Aggressive Syngeneic Mouse Model of MLL-AF9 AML

We previously showed that curaxin CBL0137 inhibits leukemia progression in KMT2A-r leukemia models (5). To investigate whether the anti-leukemic effect of the drug is potentiated when combined with HDAC targeting, we tested the combination of CBL0137 and the HDAC inhibitor panobinostat in a highly aggressive, transplantable mouse model of MLL-AF9 (KMT2A:MLLT3) leukemia. Mouse fetal liver cells were transduced with MSCV-MLL-AF9-ires-venus and MSCV-luciferase-ires-NRasG12D expression constructs (MLL-AF9;NRasG12D) as previously described (16, 17). These cells were introduced into primary recipient mice to induce leukemogenesis and then inoculated into secondary recipients for subsequent studies (Figure 1A) (16, 17). Leukemia engraftment and progression in control mice progressed rapidly as determined by whole-body bioluminescence imaging (Figure 1B). Treatment with CBL0137 and panobinostat, either alone or in combination, was started on day 4 after inoculation when all
mice presented with evidence of bone marrow engraftment based on bioluminescence signals.

CBL0137 significantly decreased leukemia burden compared to vehicle-treated mice at any given time point (Figures 1B–D and Supplementary Figure 1A) and significantly extended event free survival (EFS, CBL0137 vs control: \( P = 0.0015 \), Figure 1E and Table 1). In line with the potential of CBL0137 to induce an interferon response (15, 19, 20), the serum of mice treated with CBL0137 contained augmented levels of the chemokine Interferon γ-induced protein 10 (IP-10, CXCL10) (Supplementary Figure 2A) and splenocytes expressed higher levels of IFIT3 (Supplementary Figure 2B), demonstrating target engagement. Panobinostat alone, despite inducing accumulation of DNA damage in splenocytes of treated mice as demonstrated by increased levels of γH2AX (Supplementary Figure 2B), did not significantly change average leukemia burden or survival (Figures 1B–E). The combination of CBL0137 and panobinostat was well tolerated (Supplementary Figure 1A) and suppressed leukemia progression to the greatest extent, reducing whole body leukemia burden on average by approximately 30-fold compared to control mice one week after treatment initiation (Figure 1D). The combination provided a further therapeutic enhancement with an EFS extension of 75% compared to control mice and significantly extended EFS compared to cohorts treated with either single agent (combo vs panobinostat: \( P = 0.0013 \); combo vs CBL0137: \( P = 0.0009 \), Figure 1E and Table 1). Thus, the combination of CBL0137 and panobinostat exerts markedly enhanced inhibitory effects against this aggressive KMT2A-r AML model compared with either drug alone.

The Combination of CBL0137 and HDAC Inhibition Decreases KMT2A-r Leukemia Cell Viability

We next investigated whether the observed anti-leukemic effects of the CBL0137/panobinostat drug combination could be confirmed in human-derived KMT2A-r leukemia cells. We firstly assessed the impact of CBL0137 and panobinostat, as single agents and in combination, on the viability of low-passage leukemia cell lines derived from infants with poor outcome KMT2A-r ALL in formal synergy assays. Infant KMT2A-r leukemia cells (PER-703, PER-485, PER-494) were exposed to CBL0137 or panobinostat either alone or in combination in a 6 x 6 combination matrix and the effect of the drugs on cell viability was assessed in resazurin-reduction based viability assays. Synergy analysis was performed on the viability data according to the Bliss Independence model and showed the occurrence of mainly additive effects between the two drugs (Figure 2A and Supplementary Figures 3, 4) (21). The additive nature of the CBL0137/panobinostat combination was subsequently confirmed in longer term colony formation assays (Supplementary Figure 5). While no convincing synergy was observed between CBL0137 and panobinostat in KMT2A-r leukemia cells in vitro, for certain drug concentration combinations, significantly decreased colony numbers were observed after combination treatment compared to vehicle-treated cells (Figure 2B). The observed additive inhibitory effect of the combination of CBL0137 and panobinostat on the viability of KMT2A-r leukemia cells was not specific to KMT2A-translocated leukemias and was also observed for KMT2A-wildtype leukemias (Supplementary Figure 6).
Given that curaxin CBL0137 inhibits KMT2A-r leukemia cell growth by rapidly inducing apoptosis (5), we next determined whether HDAC inhibition boosted CBL0137-induced apoptosis by measuring the level of annexin V+ cells. Treatment of PER-485 and PER-703 cells with the CBL0137 and panobinostat combination significantly increased the percentage of annexin V+ cells within 24 hours of treatment compared to vehicle treatment (Figure 2C), indicative of rapid induction of apoptosis. Only minor effects were observed on cell cycle progression of cells treated with the combination (Supplementary Figure 7). The observed effects of the combination on KMT2A-r leukemia cell survival were associated with downregulated expression of genes involved in proliferation and cell cycle progression including MKI67, CCNB1, CENPV, CDK4 and cMYC in infant KMT2A-r leukemia cells PER-485, PER-703 and PER-494 (Figure 2D).

Similarly, a significantly increased level of apoptotic cells was observed when infant KMT2A-r leukemia cells were treated with CBL0137 in combination with another HDAC inhibitor, entinostat (Supplementary Figure 8), confirming that the enhanced anti-leukemic effect provided above by panobinostat in combination treatment involves its inhibitory action on deacetylation.

KMT2A-r leukemia is characterized by chromatin remodeling, epigenetic modifications and changes in histone marks (22, 23). As both CBL0137 and panobinostat impact chromatin structure, we investigated whether the additive effects of the drug combination were mediated by changes in histone acetylation levels or in histone marks associated with KMT2A translocations. We assessed the effect of in vitro treatment with the single agents and drug combination on histone H3 acetylation levels (total H3Ac and H3K27Ac), predicted to be impacted by panobinostat, and levels of trimethylated H3K4 (H3K4me3), a histone mark implicated in the pathobiology of KMT2A rearrangements (22, 24). While panobinostat, as expected, increased levels of acetylated total histone H3 and H3K27, the combination of CBL0137 and panobinostat did not further enhance this effect (Supplementary Figure 9). Similarly, while panobinostat treatment boosted the levels of tri-methylated H3K4 (H3K4me3) as previously described (24), the addition of CBL0137 did not further increase H3K4me3 levels. In line with the absence of an enhanced effect by the CBL0137/panobinostat drug combination on histone marks in KMT2A-r leukemia cells, we observed that the drug combination did not change expression levels of HOXA9 and MEIS1 genes, well-described leukemogenic target genes of KMT2A-r fusion proteins and upregulated in many KMT2A-r leukemias downstream of epigenetic modifications driven by KMT2A translocations (Supplementary Figure 10) (22).

The Combination of CBL0137 and Panobinostat Exhibits Potent Anti-Leukemic Activity in an Infant KMT2A-r ALL Patient-Derived Xenograft (PDX) Model

We subsequently examined the efficacy of the CBL0137 and panobinostat combination in a highly aggressive human PDX...
model of infant KMT2A-r ALL (MLL-6), which harbors a KMT2A:MLLT1 rearrangement (25, 26). PDX cells were inoculated intravenously into NOD/SCID mice, and leukemia engraftment and progression were assessed weekly by determining the percentage of circulating human CD45+ (huCD45+) leukemia cells as a proportion of total CD45+ cells (Figure 3A). Treatment was started when the median % huCD45+ cells in the blood exceeded 1% and drug efficacy was evaluated based on the circulating levels of huCD45+ cells as previously described (12, 27).

CBL0137 and panobinostat were administered according to administration regimens that were previously shown to enable target engagement (5, 15). CBL0137 induced the activation of the P53 pathway as previously described and treatment with panobinostat increased levels of acetylated histone H3 and H3K27 in leukemic blasts in mouse spleens, confirming effective inhibition of histone deacetylase activity by the drug (Supplementary Figure 11).

Leukemia progressed quickly in control mice with median EFS of just 10 days (Figure 3B; Supplementary Figure 12A; Table 1). Treatment was well tolerated with no significant weight loss in the majority of mice (Supplementary Figure 12B; Table 1). While leukemia engraftment was delayed in mice treated with CBL0137 or panobinostat as a single agent, the combination of both drugs was able to reduce circulating levels of leukemic blasts below 1% throughout a substantial proportion of the treatment period in the majority of mice (Figures 3B, C). However, in line with our in vitro studies, this enhanced effect by the combination was not associated with increased levels of acetylated H3 or H3K27, or changes in levels of KMT2A translocation associated histone marks H3K4me3 or H3K79me2 compared to the single agent treatment (Supplementary Figure 11B) (22).

CBL0137 and panobinostat as monotherapies induced EFS extensions of 131% and 86% compared to control mice, respectively, and significant differences were observed between the median EFS of the treated cohorts versus control.
The combination of CBL0137 and panobinostat (PNB) limits infant KMT2A-r ALL PDX progression. (A) Schematic of the infant KMT2A-r ALL PDX model. (B) Leukemia cell levels as measured by enumeration of the % huCD45+ cells in the peripheral blood of individual mice over time. (C) Comparison of % huCD45+ cells in blood of treated mice on day 14 post treatment initiation. Each dot corresponds to one mouse. Statistical significance of differences in mean engraftment between groups was determined by ANOVA followed by Tukey’s multiple comparison test. (D) Kaplan-Meier survival plot with endpoint defined as % huCD45+ cells in the peripheral blood reaching 25% or higher. The solid bar below the survival graphs represents treatment duration for PNB and arrows indicate CBL0137 administration. The Gehan-Wilcoxon test was used to compare survival between treatment groups. P-values comparing survival of control and treatment groups are denoted directly next to the legend. Asterisks represent significance levels of P values: *P < 0.05, **P < 0.01; ***P < 0.0001.

**DISCUSSION**

Based on the urgent need to identify better and safer treatment options for leukemias driven by a rearrangement of the KMT2A gene, we report on a novel, clinically applicable combination of anti-cancer drugs, the curaxin CBL0137 and the HDAC inhibitor panobinostat, that displays significant efficacy in aggressive animal models of KMT2A-r leukemia. In contrast to several other therapies for KMT2A-r leukemias that are focused on targeting the disease-associated aberrant epigenome, this drug combination rapidly induces apoptotic cell death, within one to two days of treatment in vitro.

Both CBL0137 and panobinostat decondense chromatin respectively by destabilising nucleosomes and by increasing histone acetylation levels. These ‘chromatin damaging’ effects are thought to selectively impact cancer cells as these cells often exhibit, and are dependent on, altered chromatin morphology (28). Chromatin decondensation provokes a host of downstream anti-cancer processes. The observed inhibitory effects of chromatin damaging drugs on cancer cells can result from modulation of different downstream anti-cancer mechanisms,
depending on the specific wiring of the cancer type under investigation. This is showcased by our previous findings on the effectiveness of the combination of CBL0137 and panobinostat in models of other high-risk pediatric cancers including neuroblastoma and diffuse intrinsic pontine glioma (DIPG) (15, 29). The CBL0137/panobinostat combination induced enhanced interferon signaling which increased the combination efficacy in immunocompetent neuroblastoma models, while the restoration of histone H3 acetylation and trimethylation was deemed to be critical for the boosted therapeutic effects of the combination in preclinical models of DIPG harboring mutant histone H3 (15, 29).

To our knowledge, this is the first report on the efficacy of the CBL0137/panobinostat combination approach to treat pediatric hematological malignancies. As KMT2A-r leukemia is driven by aberrant, oncogenic KMT2A fusion proteins that activate a hematopoietic stem cell-like transcriptional program by modifying the cell’s epigenome and chromatin structure (30), this leukemia subtype would in principle make an excellent target for drugs that affect chromatin organization. In particular, infants with KMT2A-r ALL would be ideal candidates given that the disease is primarily driven by the leukemogenic KMT2A fusion gene signature with the near absence of other driver mutations (31). However, the CBL0137/panobinostat combination did not induce significant changes in the levels of acetylation or methylation of specific histones associated with KMT2A-r leukemia or in the expression levels of leukemogenic KMT2A target genes such as HOXA9 and MEIS1 before induction of apoptosis. This indicates that the observed therapeutic enhancement by the drug combination is not mediated through a concerted effect of the drugs on histone marks. However, we did observe attenuation of the expression of several genes involved in cell proliferation and cell cycle, including cMYC in KMT2A-r leukemia cells treated with the drug combination. This is in agreement with other studies reporting that CBL0137 as well as panobinostat attenuate MYC oncogene expression in cancer cells (32, 33).

The observed cooperative effects of the CBL0137 and panobinostat combination appeared less pronounced in vitro than in the in vivo setting where the combination showed significant delays in leukemia progression compared to single agents in two highly aggressive KMT2A-r leukemia models. These results suggest that additional changes in the tumor microenvironment induced by the drugs may further contribute to the observed therapeutic enhancement. On the other hand, it is becoming increasingly clear that the true mechanistic basis for the success of multidrug combinations in animals and humans in vivo remains largely obscure (34, 35). Recent studies by Palmer et al. indicate that independent drug actions and variability between animals/patients are sufficient to explain the superiority of many approved drug combinations and that drug synergy or additivity might not come into play (34, 35). This implies that caution is warranted in interpreting the significance of putative mechanisms of synergy or enhancement identified in in vitro and in vivo experimental models.

Nevertheless, while the exact underlying mechanisms of therapeutic enhancement for this combination treatment in KMT2A-r leukemia remain difficult to delineate, the observed enhancement of treatment response upon combining these drugs in our animal models showcases the potential clinical significance of the drug combination and provides impetus for further preclinical and clinical evaluation. It will thereby be of interest to investigate how this drug combination can be incorporated into current treatment regimens. Despite our finding that the CBL0137/panobinostat drug combination significantly extends survival, all leukemia-engrafted mice still succumbed to disease. This suggests that the drug combination may have most value as an add-on therapy, administered simultaneously with standard of care agents or added into the treatment scheme sequentially after standard of care, rather than as a standalone treatment.

In conclusion, this study proposes the combination of CBL0137 and panobinostat as a candidate therapeutic approach for KMT2A-r leukemia that warrants further investigation.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The animal study was reviewed and approved by the University of New South Wales Animal Care and Ethics Committee.

AUTHOR CONTRIBUTIONS
MK, LX, AB, ER, AK, AE-A, JS, and KS conducted the experiments. MK, LX, ER, and KS analyzed the data. JS and BC provided guidance on cell cycle experiments. LC and RK provided guidance and access to the cell lines used in the study. JR and GA executed and analyzed the AlphaLISA for IP-10. AN, SB, and RJ provided guidance on experiments with the MLL-AF9/NRasG12D model and access to cells used for transplantation. RL provided guidance and access to PDX cells. LX, MH, MN, MJH, and KS conceived the project and designed the experiments. AG and KG provided support with study design. LX and KS wrote the manuscript under the guidance of MH, MJH, and MN who critically reviewed the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING
LX has received grants from Cancer Institute NSW (ECF171127), Tour de Cure and Neuroblastoma Australia. KS is supported by funding from the Kids Cancer Alliance (KCA). KS, MJH, MH, and MN are supported by a grant awarded
through the Priority-driven Collaborative Cancer Research Scheme and co-funded by Cancer Australia and The Kids’ Cancer Project (APP1164865) and philanthropy from Tenix Foundation. SB is supported by a Cancer Council Victoria (CCV) Postdoctoral Fellowship. The laboratory of RJ was supported by the Cancer Council of Victoria, National Health and Medical Research Council of Australia (NHMRC) and The Kids’ Cancer Project, and the Peter MacCallum Foundation and Australian Cancer Research Foundation provide generous support for equipment and core facilities. RL is supported by National Health and Medical Research Council of Australia (NHMRC) Fellowships APP1059804 and APP1157871. MJH and MH are recipients of a grant from Anthony Rote Memorial Trust for this work. MH and MN are supported by grants from NHMRC (APPI132608 and APPI085411), Cancer Institute NSW (14/TPG/1-13) and Cancer Council NSW (PG 16-01). LC and RK are supported by the Children’s Leukemia and Cancer Research Foundation.

ACKNOWLEDGMENTS

We would like to thank the Animal Facility and Anick Standley at Children’s Cancer Institute for providing technical assistance with the animal experiments executed during this project. The authors would like to acknowledge Dr Tzong-Tyng Hung at the Biological Resources Imaging Laboratory of the University of New South Wales for his technical assistance with bioluminescent imaging. Children’s Cancer Institute is affiliated with UNSW Sydney and the Sydney Children’s Hospital Network.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.863329/full#supplementary-material

REFERENCES

1. Muntean AG, Hess JL. The Pathogenesis of Mixed-Lineage Leukemia. Annu Rev Pathol (2012) 7:283–301. doi: 10.1146/annurev-pathol-011811-132434
2. Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina I, Renneville A, et al. The MLL Recombinome of Acute Leukemias in 2017. Leukemia (2018) 32(2):273–84. doi: 10.1038/leu.2017.213
3. Pieters R, De Lorenzo P, Andcliffe P, Aversa LA, Brethren B, Biondi A, et al. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With The Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol (2019) 37 (25):3246–56. doi: 10.1200/JCO.19.00261
4. Brown P, Pieters R, Biondi A. How I Treat Infant Leukemia. Blood (2019) 133 (3):205–14. doi: 10.1182/blood-2018-04-785980
5. Somers K, Kosciolek A, Bongers A, El-Ayoubi A, Karsa M, Mayoh C, et al. Potent Antileukemic Activity of Curaxin CBL0137 Against MLL-Rearranged Leukemia. Int J Cancer (2020) 147(7):1902–16. doi: 10.1002/ijc.32582
6. Gasparian AV, Burkhart CA, Purmal AA, Brodsky I, Pal M, Saranadasa M, et al. Curaxins: Anticancer Compounds That Simultaneously Suppress NF-kappaB and Activate P35 by Targeting FACT. Sci Transl Med (2011) 3 (95):95ra74. doi: 10.1126/scitranslmed.3002380
7. Neshar E, Safran A, Aljahdali I, Portwood S, Wang ES, Koman I, et al. Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. Cancer Res (2018) 78(6):4314–43. doi: 10.1158/0008-5472.CAN-17-2690
8. Cuickshank MN, Ford J, Cheung LC, Heng J, Singh S, Wells J, et al. Systematic Chemical and Molecular Profiling of MLL-Rearranged Infant Acute Lymphoblastic Leukemia Reveals Efficacy of Romidepsin. Leukemia (2020) 31(1):40–50. doi: 10.1038/leu.2016.165
9. Garrido Castro P, van Roon EJH, Pinhanços SS, Trentin L, Schneider P, Kerstjens M, et al. The HDAC Inhibitor Panobinostat (LB589) Exerts In Vivo Anti-Leukemic Activity Against MLL-Rearranged Acute Lymphoblastic Leukemia and Involves the RNF20/RNF40/WAC-H2B Ubiquitination Axis. Leukemia (2018) 32(2):323–31. doi: 10.1038/leu.2017.216
10. Jung M, Gao J, Cheung L, Bongers A, Somers K, Clifton M, et al. ARCCA/MRP4 Contributes to the Aggressiveness of Myc-Associated Epithelial Ovarian Cancer. Int J Cancer (2020) 147(8):2225–38. doi: 10.1002/ijc.33005
11. Somers K, Chudakov DA, Middlemass SMC, Wen VW, Clifton M, Kwek A, et al. CCI-007, A Novel Small Molecule With Cytotoxic Activity Against Infant Leukemia With MLL Rearrangements. Oncotarget (2016) 7(29):46067–87. doi: 10.18632/oncotarget.10022
12. Somers K, Evans K, Cheung L, Karsa M, Pritchard T, Kosciolek A, et al. Effective Targeting of NAMPT in Patient-Derived Xenograft Models of High-Risk Pediatric Acute Lymphoblastic Leukemia. Leukemia (2020) 34(6):1524–39. doi: 10.1038/s41375-019-0683-6
13. Gamble LD, Purgato S, Murray J, Xiao L, Yu DMT, Hanssen KM, et al. Inhibition of Polyamine Synthesis and Uptake Reduces Tumor Progression and Prolongs Survival in Mouse Models of Neuroblastoma. Sci Trans Med (2019) 11(477):eaau1099. doi: 10.1126/scitransmed.eaau1099
14. Karsa M, Ronca E, Bongers A, Mariana A, Moles E, Faiies TW, et al. Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia. Front Oncol (2021) 11:779859. doi: 10.3389/fonc.2021.779859
15. Xiao L, Somers K, Murray J, Pandher R, Karsa M, Ronca E, et al. Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. Clin Cancer Res (2021) 27(15):4338–52. doi: 10.1158/1078-0432.CCR-20-2357
16. Bots M, Verbrugge I, Martin BP, Salmon M, Ghisi M, Baker A, et al. Differentiation Therapy for the Treatment of T(8;21) Acute Myeloid Leukemia Using Histone Deacetylase Inhibitors. Blood (2014) 123(9):1341–52. doi: 10.1182/blood-2013-04-488114
17. Baker A, Gregory GP, Verbrugge I, Kats L, Hilton JJ, Vidas E, et al. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia. Cancer Res (2016) 76(5):1158–69. doi: 10.1158/0008-5472.CAN-15-1070
18. Rose WC, Wild R. Therapeutic Synergy of Oral Taxane BM5-275183 and Cetuximab Versus Human Tumor Xenografts. Clin Cancer Res (2004) 10 (21):7413–7. doi: 10.1158/1078-0432.CCR-04-1045
19. Leonova K, Safina A, Neshar E, Sandlesh P, Pratt R, Burkhart C, et al. TRAIN (Transcription of Repeats Activates INterferon) in Response to Chromatin Destabilization Induced by Small Molecules in Mammalian Cells. Elife (2018) 7:e30842. doi: 10.7554/eLife.30842
20. Chen M, Brackett CM, Burdelya LG, Punnanitinont A, Patnaik SK, Matsuzaki Y, et al. The Anti-Leukaemic Activity Against MLL-Rearranged Acute Lymphoblastic Leukemia and Involves the RNF20/RNF40/WAC-H2B Ubiquitination Axis. Blood (2018) 133(9):1341–52. doi: 10.1182/blood-2017-04-760432.CCR-20-2357
21. Cheung LC, de Kraa R, Oommen J, Chua GA, Singh S, Hughes AM, et al. Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia. Front Oncol (2021) 11:631594. doi: 10.3389/fonc.2021.631594
22. Chen AKN, Chen CW. Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions. Front Cell Dev Biol (2019) 7:81. doi: 10.3389/fcel.2019.00081

Frontiers in Oncology | www.frontiersin.org May 2022 | Volume 12 | Article 863329 9

Xiao et al. A Novel Treatment for KMT2A-Rearranged Leukemia
23. Wong SHK, Goode DL, Iwasaki M, Wei MC, Kuo HP, Zhu L, et al. The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential. *Cancer Cell* (2015) 28(2):198–209. doi: 10.1016/j.ccell.2015.06.003

24. Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SGT, Liu K, et al. Highly Effective Combination of LSD1 (KDM1A) Antagonist and Pan-Histone Deacetylase Inhibitor Against Human AML Cells. *Leukemia* (2014) 28(11):2155–64. doi: 10.1038/leu.2014.119

25. Rokita JL, Rathi KS, Cardenas MF, Upton KA, Jayaseelan J, Cross KL, et al. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. *Cell Rep* (2019) 29(6):1675–89.e9. doi: 10.1016/j.celrep.2019.09.071

26. Richmond J, Carol H, Evans K, High L, Mendomo A, Robbins A, et al. Effective Targeting of the P53-MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia. *Clin Cancer Res* (2015) 21(6):1395–405. doi: 10.1158/1078-0432.CCR-14-2300

27. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, et al. The Pediatric Preclinical Testing Program: Description of Models and Early Testing Results. *Pediatr Blood Cancer* (2007) 49(7):928–40. doi: 10.1002/pbc.21078

28. Gurova KV. Chromatin Stability as a Target for Cancer Treatment. *Bioessays* (2019) 41(1):c1800141. doi: 10.1002/bies.201800141

29. Ehteda A, Simon S, Franshaw L, Giorgi FM, Liu J, Joshi S, et al. Dual Targeting of the Epigenome via FACT Complex and Histone Deacetylase Is a Potent Treatment Strategy for DIPG. *Cell Rep* (2021) 35(2):108994. doi: 10.1016/j.celrep.2021.108994

30. Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL, et al. Aberrant Chromatin at Genes Encoding Stem Cell Regulators in Human Mixed-Lineage Leukemia. *Genes Dev* (2008) 22(24):3403–8. doi: 10.1101/gad.1741408

31. Beroukhim R, Merkel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The Landscape of Somatic Copy-Number Alteration Across Human Cancers. *Nature* (2010) 463(7283):899–905. doi: 10.1038/nature08822

32. Carter DR, Murray J, Cheung BB, Gamble L, Koach J, Tsang J, et al. Therapeutic Targeting of the MYC Signal by Inhibition of Histone Chaperone FACT in Neuroblastoma. *Sci Transl Med* (2015) 7(312):312ra176. doi: 10.1126/scitranslmed.aab1803

33. Carter DR, Murray J, Cheung BB, Gamble L, Koach J, Tsang J, et al. Therapeutic Targeting of the MYC Signal by Inhibition of Histone Chaperone FACT in Neuroblastoma. *Sci Transl Med* (2015) 7(312):312ra176. doi: 10.1126/scitranslmed.aab1803

34. Palmer AC, Sorger PK. Combination Cancer Therapy Can Confer Benefit via Patient-To-Patient Variability Without Drug Additivity or Synergy. *Cell* (2017) 171(7):1678–91.e13. doi: 10.1016/j.cell.2017.11.009

35. Palmer AC, Chidley C, Sorger PK. A Curative Combination Cancer Therapy Achieves High Fractional Cell Killing Through Low Cross-Resistance and Drug Additivity. *Elife* (2019) 8:e50036. doi: 10.7554/eLife.50036

**Conflict of Interest:** KG and AG are co-authors of patent WO2010/042445 “Carbazol compounds and the therapeutic use of the compounds”. KG was a recipient of research grants and consulting payments from Incuron, Inc. The laboratory of RJ receives research support from F. Hoffmann-La Roche Ltd., Astra Zeneca, BMS, and MecRx. RJ is a scientific consultant and shareholder in MecRx.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xiao, Karsa, Ronca, Bongers, Koscielak, El-Ayoubi, Revalde, Seneviratne, Cheung, Cheung, Kotecha, Newbold, Bjelosevic, Arndt, Lock, Johnstone, Gudkov, Gurova, Haber, Norris, Henderson and Somers. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.